SAN FRANCISCO — A 6-month course of oral valganciclovir improves hearing and nerve development in infants with cytomegalovirus, and works better than a 6-week course, report researchers. This is the ...

The monoclonal anti-CD52 antibody alemtuzumab is active against chronic lymphocytic leukemia and other low-grade B- and T-cell lymphoproliferative diseases. It is lymphoablative, making patients ...

On September 15, 2003, the US Food and Drug Administration changed the indications for valganciclovir (Valcyte) to include prevention of CMV disease in kidney, pancreas, and heart transplant patients.

All consecutive patients undergoing MA and reduced-intensity allogeneic stem cell transplantation at the Leiden University Medical Center between January 2001 and December 2004 were included in this ...

Review the side-effects of Valganciclovir as documented in medical literature. The term "side effects" refers to unintended effects that can occur as a result of taking the medication. In majority of ...

Please provide your email address to receive an email when new articles are posted on . SAN FRANCISCO — Six months of therapy with oral valganciclovir for infants with symptomatic congenital ...

Andre Kalil, MD VANCOUVER, British Columbia—Half of the approved dose for cytomegalovirus (CMV) prophylaxis in solid organ transplant recipients is just as effective as the approved dose and is safer, ...

Valganciclovir (Valstead) is an antiviral agent, prescribed for cytomegalovirus (CMV) retinitis.It stops the growth and reproduction of the virus. The information provided on this page is intended to ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Back to Healio SAN FRANCISCO — Valganciclovir has shown ...

Longer therapy with oral valganciclovir may modestly improve long-term developmental outcomes and hearing in neonates with symptomatic congenital cytomegalovirus (CMV) disease, reports a study in the ...

Plus new oral solution offers dosing flexibility for pediatric patients Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug Administration (FDA) has approved Valcyte ...